{"id":"W3133799417","doi":"10.1080/10428194.2021.1889536","title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Myeloid leukemia; Medicine; Nivolumab; Nilotinib; Oncology; Internal medicine; Leukemia; Immunotherapy; Cancer; Imatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001569806,0.0003281904,0.0009162657,0.0002420998,0.0008943715,0.0009889869,0.000608242,0.006566974,0.002952558],"category_scores_gemma":[0.003423574,0.0002269828,0.0005545198,0.0004832126,0.0005047396,0.000591334,0.0003101249,0.003693972,0.003225662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00268019,"about_ca_system_score_gemma":0.001328988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002543946,"about_ca_topic_score_gemma":0.008129948,"domain_scores_codex":[0.9988219,0.0004072603,0.0001582499,0.0001120184,0.0003625341,0.0001380147],"domain_scores_gemma":[0.9983501,0.0006676547,0.0001981111,0.00005507899,0.0003446605,0.0003843055],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.006329086,0.0008084265,0.01730193,0.0003208739,0.0001333322,0.009190947,0.0001705732,0.0006491497,0.007110536,0.001635624,0.7864119,0.1699376],"study_design_scores_gemma":[0.01357449,0.005810086,0.04682384,0.0004554608,0.0002677938,0.0207662,0.0002661623,0.003979561,0.005044805,0.005305796,0.8975962,0.0001095676],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.08885228,0.02778157,0.0007205217,0.8131677,0.01166453,0.0004059309,0.004070891,0.0002390639,0.05309753],"genre_scores_gemma":[0.2764775,0.01220524,0.001776228,0.6513677,0.0221605,0.0005321611,0.003193579,0.0001025094,0.03218453],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006566974,"threshold_uncertainty_score":0.01944631,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01104437647212379,"score_gpt":0.2445490745034217,"score_spread":0.2335046980312979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}